Share-based Payment Arrangement, Expense of ABVC BIOPHARMA, INC. from 30 Sep 2016 to 31 Dec 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
ABVC BIOPHARMA, INC. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Sep 2016 to 31 Dec 2024.
  • ABVC BIOPHARMA, INC. Share-based Payment Arrangement, Expense for the quarter ending 31 Dec 2024 was $225,740, a 61% decline year-over-year.
  • ABVC BIOPHARMA, INC. Share-based Payment Arrangement, Expense for the twelve months ending 31 Dec 2024 was $451,480, a 50% decline year-over-year.
  • ABVC BIOPHARMA, INC. annual Share-based Payment Arrangement, Expense for 2024 was $451,480, a 50% decline from 2023.
  • ABVC BIOPHARMA, INC. annual Share-based Payment Arrangement, Expense for 2023 was $902,960, a 87% decline from 2022.
  • ABVC BIOPHARMA, INC. annual Share-based Payment Arrangement, Expense for 2022 was $7,036,778, a 33% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

ABVC BIOPHARMA, INC. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2024 $451,480 $225,740 -$85,220 -61% 01 Oct 2024 31 Dec 2024 10-Q 03 Nov 2025 2025 Q3
Q3 2024 $536,700 $225,740 -$592,000 -72% 01 Jul 2024 30 Sep 2024 10-Q 03 Nov 2025 2025 Q3
Q2 2024 $1,128,700 $225,740 $0 0% 01 Apr 2024 30 Jun 2024 10-Q 13 Aug 2025 2025 Q2
Q1 2024 $1,128,700 $225,740 +$225,740 01 Jan 2024 31 Mar 2024 10-Q 30 Apr 2025 2025 Q1
Q4 2023 $902,960 $140,520 -$2,033,815 -107% 01 Oct 2023 31 Dec 2023 10-Q 03 Nov 2025 2025 Q3
Q3 2023 $2,936,775 $817,740 +$592,000 +262% 01 Jul 2023 30 Sep 2023 10-Q 15 Nov 2023 2023 Q3
Q2 2023 $2,344,775 $225,740 $0 0% 01 Apr 2023 30 Jun 2023 10-Q 14 Aug 2023 2023 Q2
Q1 2023 $2,344,775 $0 -$4,692,003 -100% 01 Jan 2023 31 Mar 2023 10-Q 17 May 2024 2024 Q1
Q4 2022 $7,036,778 $1,893,295 01 Oct 2022 31 Dec 2022 10-K 31 Mar 2023 2022 FY
Q3 2022 $225,740 01 Jul 2022 30 Sep 2022 10-Q 15 Nov 2023 2023 Q3
Q2 2022 $225,740 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023 2023 Q2
Q1 2022 $4,692,003 +$4,466,263 +1978% 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023 2023 Q1
Q1 2021 $225,740 +$225,215 +42898% 01 Jan 2021 31 Mar 2021 10-Q 16 May 2022 2022 Q1
Q1 2020 $525 -$8,025 -94% 01 Jan 2020 31 Mar 2020 10-Q 10 May 2021 2021 Q1
Q1 2019 $8,550 01 Jan 2019 31 Mar 2019 10-Q 29 Jun 2020 2020 Q1

ABVC BIOPHARMA, INC. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $451,480 -$451,480 -50% 01 Jan 2024 31 Dec 2024 10-Q 03 Nov 2025 2025 Q3
2023 $902,960 -$6,133,818 -87% 01 Jan 2023 31 Dec 2023 10-Q 03 Nov 2025 2025 Q3
2022 $7,036,778 +$1,730,023 +33% 01 Jan 2022 31 Dec 2022 10-K 31 Mar 2023 2022 FY
2021 $5,306,755 +$1,159,776 +28% 01 Jan 2021 31 Dec 2021 10-K 31 Mar 2023 2022 FY
2020 $4,146,979 +$4,124,665 +18485% 01 Jan 2020 31 Dec 2020 10-K 31 Mar 2022 2021 FY
2019 $22,314 -$6,486 -23% 01 Jan 2019 31 Dec 2019 10-K 16 Mar 2021 2020 FY
2018 $28,800 -$109,238 -79% 01 Jan 2018 31 Dec 2018 10-K 15 May 2020 2019 FY
2017 $138,038 -$259,922 -65% 01 Oct 2016 30 Sep 2017 10-KT 13 Apr 2018 2017 FY
2016 $397,960 01 Oct 2015 30 Sep 2016 10-KT 13 Apr 2018 2017 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.